DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension

A Phase II Study to Explore the Effect of Different Dose of DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension

The purpose of this study is to compare the different dose of DMTA07 (DM) combine with amlodipine in the treatment of mild to moderate essential hypertension, and to define the optimized dose of DM in the combination therapy.

Study Overview

• Status: Completed
• Conditions: Hypertension
• Intervention / Treatment: Drug: AM 5 + DM 0; Drug: AM 5 + DM 2.5; Drug: AM 5 + DM 7.5; Drug: AM 5 + DM 30

Detailed Description

To compare the different dose of DM combine with amlodipine in the treatment of mild to moderate essential hypertension, and to define the optimized dose of DM in the combination therapy.

The purpose of this study is to compare the antihypertensive efficacy and tolerability of different dose of DM combines with amlodipine treatment, further to explore the optimized combination dose of DM.

• Study Type: Interventional
• Enrollment (Actual): 111
• Phase: Phase 2

Contacts and Locations

Study Locations

• Taiwan
  • Kaohsiung, Taiwan, 824
    • E-DA hospital
  • Taichung, Taiwan, 40705
    • Taichung Veterans General Hospital
  • Taipei, Taiwan, 100
    • National Taiwan University Hospital
  • Taipei, Taiwan, 104
    • Mackay Memorial Hospital
  • Taipei, Taiwan, 114
    • TRI-Service General Hospital
  • Taipei, Taiwan, 112
    • Taipei Veterans General Hospital
  • Taipei, Taiwan, 112
    • Cheng Hsin General Hospital
  • Taoyuan County, Taiwan, 333
    • Chang Gung Memorial Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female patient aged between 50 to 75 years old (both included);

2. Patient with mild to moderate essential hypertension at enrollment, which defined as the following:

   Patient must have mean sitting SBP ≥140 and <180 mmHg or mean sitting DBP ≥90 and <110 mmHg at enrollment;

3. Patient with normal serum potassium;
4. Patient or his/her legally acceptance representative has signed the written informed consent form.

Exclusion Criteria:

1. Patient with severe hypertension (mean sitting DBP ≥ 110 mmHg or mean sitting SBP ≥ 180 mmHg);
2. Patient with secondary hypertension, such as coarctation of aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc;
3. Patient is under treatment with beta-blocker prior to enrollment;
4. A definite diagnosis or unstable of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, stroke, arrhythmia and heart failure within 3 months before signing the written informed consent form;
5. Patient with concomitant endocrine diseases or type 1 Diabetes Mellitus;
6. Patient with type 2 Diabetes Mellitus with poor glucose control (glycosylated hemoglobin > 9% or fasting blood sugar > 250 mg/dL at enrollment) or under insulin treatment;
7. Patient with clinically unstable disease such as known collagen or auto-immune disease or other malignant disease requiring current medication;
8. Patient with bilateral renal artery stenosis, solitary kidney or post renal transplant;
9. Patient with clinically relevant hematological disease;

10. Hepatic or renal dysfunction as defined by the following parameters:

    • ALT or AST > 2 times upper limit of normal,
    • Total bilirubin > 2 times upper limit of normal,
    • Serum creatinine >2.0 mg/dl;
11. Female patient who is pregnant or lactating;
12. Patient with substance abuse (including alcohol) history for the past two years;
13. Known or suspected contraindications, including allergy to DMTA07 or calcium channel blockers;
14. Patient received other investigational drug or device within 30 days before signing the written informed consent form;
15. Patient with any other serious disease considered by the investigator(s) not in the condition to enter the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Factorial Assignment
• Masking: Single

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: AM 5 + DM 0; Amlodipine 5 mg + DMTA07 0mg, once daily	Drug: AM 5 + DM 0; Amlodipine 5 mg + DMTA07 0mg, once daily; Other Names: Amlodipine (AM); DMTA07 (DM)
Experimental: AM 5 + DM 2.5; Amlodipine 5 mg + DMTA07 2.5mg, once daily	Drug: AM 5 + DM 0; Amlodipine 5 mg + DMTA07 0mg, once daily; Other Names: Amlodipine (AM); DMTA07 (DM); Drug: AM 5 + DM 2.5; Amlodipine 5 mg + DMTA07 2.5mg, once daily; Other Names: Amlodipine (AM); DMTA07 (DM)
Experimental: AM 5 + DM 7.5; Amlodipine 5 mg + DMTA07 7.5mg, once daily	Drug: AM 5 + DM 0; Amlodipine 5 mg + DMTA07 0mg, once daily; Other Names: Amlodipine (AM); DMTA07 (DM); Drug: AM 5 + DM 2.5; Amlodipine 5 mg + DMTA07 2.5mg, once daily; Other Names: Amlodipine (AM); DMTA07 (DM); Drug: AM 5 + DM 7.5; Amlodipine 5 mg + DMTA07 7.5mg, once daily; Other Names: Amlodipine (AM); DMTA07 (DM)
Experimental: AM 5 + DM 30; Amlodipine 5 mg + DMTA07 30mg, once daily	Drug: AM 5 + DM 0; Amlodipine 5 mg + DMTA07 0mg, once daily; Other Names: Amlodipine (AM); DMTA07 (DM); Drug: AM 5 + DM 2.5; Amlodipine 5 mg + DMTA07 2.5mg, once daily; Other Names: Amlodipine (AM); DMTA07 (DM); Drug: AM 5 + DM 7.5; Amlodipine 5 mg + DMTA07 7.5mg, once daily; Other Names: Amlodipine (AM); DMTA07 (DM); Drug: AM 5 + DM 30; Amlodipine 5 mg + DMTA07 30mg, once daily; Other Names: Amlodipine (AM); DMTA07 (DM)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
*SBP reduction=SBP each visit- SBPvisit2	The primary objective of this study is to compare the sitting systolic blood pressure (mmHg) reduction* between four dose regimens, the baseline is defined as the actual SBP value after 2 weeks of amlodipine run-in period	14 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The secondary objectives of the study include: Efficacy/Safety	Efficacy: To compare the sitting diastolic blood pressure (mmHg) reduction* between four dose regimens, the baseline is defined as the actual DBP value after 2 weeks of amlodipine run-in period To evaluate the percentage of SBP reduction in four treatment regimens To evaluate the changes of blood pressure (mmHg) in different clusters; such as diabetes etc. Safety: To evaluate the pulse rate changes To evaluate incidences of adverse events To evaluate the change of laboratory test results from baseline	14 weeks

Collaborators and Investigators

• Sponsor: TSH Biopharm Corporation Limited
• Investigators: Principal Investigator: Jaw-Wen Chen, Doctor, VGHTP

Study record dates

Study Major Dates

• Study Start: July 1, 2012
• Primary Completion (Actual): May 1, 2014
• Study Completion (Actual): May 1, 2014

Study Registration Dates

• First Submitted: June 3, 2012
• First Submitted That Met QC Criteria: June 5, 2012
• First Posted (Estimate): June 7, 2012

Study Record Updates

• Last Update Posted (Estimate): November 13, 2015
• Last Update Submitted That Met QC Criteria: November 11, 2015
• Last Verified: November 1, 2015

More Information

Terms related to this study

• Keywords: hypertension; amlodipine; DMTA07
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Hypertension; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antihypertensive Agents; Vasodilator Agents; Membrane Transport Modulators; Calcium-Regulating Hormones and Agents; Calcium Channel Blockers; Amlodipine
• Other Study ID Numbers: TSHDM1101; DMTA07 (Other Identifier: Tshbiopharm)